FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890706095> ?p ?o ?g. }

• W2890706095 endingPage "12" @default.
• W2890706095 startingPage "1" @default.
• W2890706095 abstract "Purpose Parallel activation of the phosphatidylinositol 3-kinase–mammalian target of rapamycin pathway represents a mechanism of primary and acquired resistance to BRAF-targeted therapy, but the two pathways have yet to be cotargeted in humans. We performed a phase I study to evaluate the safety and activity of the BRAF inhibitor vemurafenib in combination with the mammalian target of rapamycin inhibitor everolimus in BRAF-mutated advanced solid tumors. Patients and Methods We performed a 3+3 dose-escalation study with escalating doses of both oral (PO) vemurafenib administered twice a day and PO everolimus administered daily. Results Twenty patients with advanced cancers were enrolled. The median adult age was 64 years (range, 17 to 85 years); two pediatric patients were 10 and 13 years old. Patients were heavily pretreated with prior BRAF or MEK inhibitors (n = 11), phase I clinical trial therapy (n = 10), surgery (n = 18), radiation therapy (n = 11), and chemotherapy (n=13). One of the two pediatric patients initially experienced grade 3 rash, but after dermatologic intervention, the patient remains on trial with partial response and no dose reduction at time of analysis. Four dose-limiting toxicities (rash, n = 1; fatigue, n = 3) were observed at dose level 2. Therefore, dose level 1 (vemurafenib 720 mg PO twice a day and everolimus 5 mg PO daily) was the maximum-tolerated dose. Overall, four patients (22%) had a partial response and nine patients (50%) had stable disease as best response. One pediatric patient with pleomorphic xanthroastrocytoma remains on protocol with continued clinical response after 38 cycles. Conclusion The combination of vemurafenib 720 mg PO twice a day and everolimus 5 mg PO daily is safe and well tolerated and has activity across histologies, with partial responses noted in advanced non–small-cell lung cancer, melanoma, optic nerve glioma, and xanthroastrocytoma, including patients who previously experienced progression on BRAF and/or MEK inhibitor therapy. Further investigation in a larger cohort of molecularly matched patients is warranted." @default.
• W2890706095 created "2018-09-27" @default.
• W2890706095 creator A5005194857 @default.
• W2890706095 creator A5008786567 @default.
• W2890706095 creator A5024356241 @default.
• W2890706095 creator A5026095888 @default.
• W2890706095 creator A5033798832 @default.
• W2890706095 creator A5040716806 @default.
• W2890706095 creator A5043675371 @default.
• W2890706095 creator A5043723479 @default.
• W2890706095 creator A5044840107 @default.
• W2890706095 creator A5069777765 @default.
• W2890706095 creator A5071800834 @default.
• W2890706095 creator A5076426660 @default.
• W2890706095 creator A5084622735 @default.
• W2890706095 creator A5090510992 @default.
• W2890706095 date "2018-11-01" @default.
• W2890706095 modified "2023-10-18" @default.
• W2890706095 title "Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With <i>BRAF</i>-Mutated Malignancies" @default.
• W2890706095 cites W1523640001 @default.
• W2890706095 cites W1846586690 @default.
• W2890706095 cites W1876354503 @default.
• W2890706095 cites W1965370740 @default.
• W2890706095 cites W2004010079 @default.
• W2890706095 cites W2009642188 @default.
• W2890706095 cites W2032211985 @default.
• W2890706095 cites W2032487001 @default.
• W2890706095 cites W2049282019 @default.
• W2890706095 cites W2072580848 @default.
• W2890706095 cites W2096387850 @default.
• W2890706095 cites W2104697581 @default.
• W2890706095 cites W2106410630 @default.
• W2890706095 cites W2107519665 @default.
• W2890706095 cites W2110355778 @default.
• W2890706095 cites W2111580893 @default.
• W2890706095 cites W2131040858 @default.
• W2890706095 cites W2137586470 @default.
• W2890706095 cites W2140318778 @default.
• W2890706095 cites W2163188200 @default.
• W2890706095 cites W2163655212 @default.
• W2890706095 cites W2179502834 @default.
• W2890706095 cites W2206684187 @default.
• W2890706095 cites W2256515178 @default.
• W2890706095 cites W2303146341 @default.
• W2890706095 cites W2357590829 @default.
• W2890706095 cites W2409383155 @default.
• W2890706095 cites W2471562228 @default.
• W2890706095 cites W2613362156 @default.
• W2890706095 cites W2749165674 @default.
• W2890706095 cites W2766581537 @default.
• W2890706095 cites W3164126191 @default.
• W2890706095 doi "https://doi.org/10.1200/po.18.00189" @default.
• W2890706095 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7446411" @default.
• W2890706095 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32913986" @default.
• W2890706095 hasPublicationYear "2018" @default.
• W2890706095 type Work @default.
• W2890706095 sameAs 2890706095 @default.
• W2890706095 citedByCount "10" @default.
• W2890706095 countsByYear W28907060952020 @default.
• W2890706095 countsByYear W28907060952021 @default.
• W2890706095 countsByYear W28907060952022 @default.
• W2890706095 countsByYear W28907060952023 @default.
• W2890706095 crossrefType "journal-article" @default.
• W2890706095 hasAuthorship W2890706095A5005194857 @default.
• W2890706095 hasAuthorship W2890706095A5008786567 @default.
• W2890706095 hasAuthorship W2890706095A5024356241 @default.
• W2890706095 hasAuthorship W2890706095A5026095888 @default.
• W2890706095 hasAuthorship W2890706095A5033798832 @default.
• W2890706095 hasAuthorship W2890706095A5040716806 @default.
• W2890706095 hasAuthorship W2890706095A5043675371 @default.
• W2890706095 hasAuthorship W2890706095A5043723479 @default.
• W2890706095 hasAuthorship W2890706095A5044840107 @default.
• W2890706095 hasAuthorship W2890706095A5069777765 @default.
• W2890706095 hasAuthorship W2890706095A5071800834 @default.
• W2890706095 hasAuthorship W2890706095A5076426660 @default.
• W2890706095 hasAuthorship W2890706095A5084622735 @default.
• W2890706095 hasAuthorship W2890706095A5090510992 @default.
• W2890706095 hasBestOaLocation W28907060952 @default.
• W2890706095 hasConcept C121608353 @default.
• W2890706095 hasConcept C126322002 @default.
• W2890706095 hasConcept C143998085 @default.
• W2890706095 hasConcept C184235292 @default.
• W2890706095 hasConcept C197934379 @default.
• W2890706095 hasConcept C2776131300 @default.
• W2890706095 hasConcept C2778570526 @default.
• W2890706095 hasConcept C2779699572 @default.
• W2890706095 hasConcept C2781249067 @default.
• W2890706095 hasConcept C2994587330 @default.
• W2890706095 hasConcept C31760486 @default.
• W2890706095 hasConcept C535046627 @default.
• W2890706095 hasConcept C57074206 @default.
• W2890706095 hasConcept C71924100 @default.
• W2890706095 hasConcept C86803240 @default.
• W2890706095 hasConcept C95444343 @default.
• W2890706095 hasConcept C98274493 @default.
• W2890706095 hasConceptScore W2890706095C121608353 @default.
• W2890706095 hasConceptScore W2890706095C126322002 @default.
• W2890706095 hasConceptScore W2890706095C143998085 @default.

• next